Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyo Young, Jun, Dae Won, Kim, Hyun Jung, Oh, Hyunwoo, Saeed, Waqar Khalid, Ahn, Hyeongsik, Cheung, Ramsey C., Nguyen, Mindie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406097/
https://www.ncbi.nlm.nih.gov/pubmed/29551054
http://dx.doi.org/10.3904/kjim.2017.194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406097/
https://www.ncbi.nlm.nih.gov/pubmed/29551054
http://dx.doi.org/10.3904/kjim.2017.194

Ejemplares similares